KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Assets (2018 - 2025)

Historic Assets for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $364.0 million.

  • Esperion Therapeutics' Assets rose 1588.79% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.0 million, marking a year-over-year increase of 1588.79%. This contributed to the annual value of $343.8 million for FY2024, which is 6706.88% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Assets is $364.0 million, which was up 1588.79% from $347.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Assets registered a high of $381.6 million during Q4 2021, and its lowest value of $205.8 million during Q4 2023.
  • Moreover, its 5-year median value for Assets was $312.8 million (2022), whereas its average is $300.3 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Assets tumbled by 3502.48% in 2022, and later skyrocketed by 6706.88% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Assets (Quarter) stood at $381.6 million in 2021, then plummeted by 35.02% to $247.9 million in 2022, then fell by 17.0% to $205.8 million in 2023, then surged by 67.07% to $343.8 million in 2024, then increased by 5.87% to $364.0 million in 2025.
  • Its Assets stands at $364.0 million for Q3 2025, versus $347.1 million for Q2 2025 and $324.0 million for Q1 2025.